NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

Company Overview

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $0.38 to $0.38
• 50-Day Range: $0.38 to $0.38
• 52-Week Range: $0.36 to $4.80
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $1.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NBSE Stock Analysis - Frequently Asked Questions

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its quarterly earnings data on Thursday, December, 23rd. The company reported ($4.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.60) by $0.40.

When did NeuBase Therapeutics' stock split?

NeuBase Therapeutics shares reverse split before market open on Thursday, June 15th 2023.The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Pfizer (PFE), Energy Transfer (ET), Sio Gene Therapies (SIOX), Avino Silver & Gold Mines (ASM), Actinium Pharmaceuticals (ATNM), Cytokinetics (cytk) and Enbridge (enb).

Company Calendar

• Last Earnings: 12/23/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NBSE
• CIK: 1173281
• Web: www.neubasetherapeutics.com
• Phone: (164) 645-1790
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,750,000
• Free Float: 3,456,000
• Market Cap: $1.43 million
• Optionable: Not Optionable
• Beta: N/A